 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ritivixibat (IPN60250) / Ipsen
Enrollment change: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis (clinicaltrials.gov) - Jan 23, 2024
P2, N=24, Recruiting, Sponsor: Albireo
N=12 --> 24
- | ritivixibat (IPN60250) / Ipsen
Trial completion date, Trial primary completion date: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis (clinicaltrials.gov) - Jan 2, 2024
P2, N=12, Recruiting, Sponsor: Albireo
N=12 --> 24 Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- A3907 / Ipsen
A3907, a systemic ASBT inhibitor, improves cholestasis in mice by inhibiting multi-organ bile acid transport and shows translational relevance to human (Stolz 1) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_2345;
A3907 was well-tolerated in human subjects at doses reaching systemic exposures comparable to those required for therapeutic effects in animal models of cholestasis. Collectively these results highlight the promising translational potential of A3907 for the treatment of cholestatic diseases.
- || ritivixibat (IPN60250) / Ipsen
Enrollment open: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis (clinicaltrials.gov) - Jan 25, 2023
P2, N=12, Recruiting, Sponsor: Albireo
Collectively these results highlight the promising translational potential of A3907 for the treatment of cholestatic diseases. Not yet recruiting --> Recruiting
- | ritivixibat (IPN60250) / Ipsen
Trial completion date, Trial primary completion date: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis (clinicaltrials.gov) - Jan 17, 2023
P2, N=12, Not yet recruiting, Sponsor: Albireo
Not yet recruiting --> Recruiting Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- || ritivixibat (IPN60250) / Ipsen
New P2 trial: Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis (clinicaltrials.gov) - Dec 8, 2022
P2, N=12, Not yet recruiting, Sponsor: Albireo
- A3907 / Albireo
SYSTEMIC ASBT INHIBITION WITH A3907 STIMULATES URINARY EXCRETION OF BILE ACIDS AND HALTS LIVER DISEASE PROGRESSION IN BILE-DUCT–OBSTRUCTED MICE () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1652;
Inhibition of renal ASBT with A3907 improved the general condition and liver phenotype of mice with induced obstructive cholestasis, by promoting urinary secretion of BAs. A3907 may have therapeutic potential for patients with cholestatic liver diseases.